Literature DB >> 11734240

Infliximab-induced aseptic meningitis.

H Marotte, J E Charrin, P Miossec.   

Abstract

We report an episode of aseptic meningitis in a 53-year-old man, who was treated with infliximab for active rheumatoid arthritis. He had acute, severe muscle pain after initial infusion of the drug, and similar symptoms with a transient lymphocytic meningitis after a subsequent infusion. We measured no change in antibodies to nuclei, DNA, or to neurones. Functional antibodies to infliximab were not induced and concentrations of tumour necrosis factor a in spinal fluid were not raised. This adverse reaction to infliximab might have been caused by inability of the drug to enter the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734240     DOI: 10.1016/S0140-6736(01)06810-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.

Authors:  R Quispel; H B van der Worp; M Pruissen; M E Schipper; B Oldenburg
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

2.  Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.

Authors:  Antonio Salar; Xavier Bessa; Eduard Muñiz; David Monfort; Carlos Besses; Montserrat Andreu
Journal:  Gut       Date:  2007-03-07       Impact factor: 23.059

Review 3.  Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart.

Authors:  P A Henriksen; D E Newby
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

Review 4.  Targeting IL-17 and TH17 cells in chronic inflammation.

Authors:  Pierre Miossec; Jay K Kolls
Journal:  Nat Rev Drug Discov       Date:  2012-10       Impact factor: 84.694

5.  Bacterial meningitis associated with infliximab.

Authors:  Raymond Farah; Svetlana Lisitsin; Moshe Shay
Journal:  Pharm World Sci       Date:  2006-09-27

6.  Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany.

Authors:  Thomas Witthöft; Diether Ludwig
Journal:  Int J Colorectal Dis       Date:  2004-09-30       Impact factor: 2.571

7.  A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.

Authors:  Thomas S Lin; Wendy Stock; Huiping Xu; Mitch A Phelps; Margaret S Lucas; Sara K Guster; Bruce R Briggs; Carolyn Cheney; Pierluigi Porcu; Ian W Flinn; Michael R Grever; James T Dalton; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-12

8.  Rheumatoid meningitis: successful remission with rituximab.

Authors:  Nancy Salloum Harrison; Shweta Kishore; Vikas Majithia
Journal:  BMJ Case Rep       Date:  2018-12-31

Review 9.  Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.

Authors:  Elsa How Shing Koy; Pierre Labauge; Athan Baillet; Clément Prati; Hubert Marotte; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-09       Impact factor: 5.346

Review 10.  Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

Authors:  Juergen Braun; Joachim Sieper
Journal:  Arthritis Res       Date:  2002-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.